Is Sangani Hospital overvalued or undervalued?

As of 16 October 2025, Sangani Hospital's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 35.88, an EV to EBITDA of 30.42, and a ROCE of 10.33%.
In comparison to its peers, Sangani Hospital's valuation stands out as more favorable; for instance, Apollo Hospitals has a significantly higher PE ratio of 71.71, while Max Healthcare is even more expensive at 94.88. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -7.48% compared to the Sensex's 8.21%, the attractive valuation suggests that Sangani Hospital may present a compelling investment opportunity in the current market.